OBJECTIVE: The aim of this study was to analyze the correlation among the expression of caveolin-1, the protein constituent of caveolae, and disease outcome in advanced-stage ovarian carcinomas. METHODS: Sections from 76 primary ovarian carcinomas and metastatic lesions from 45 patients diagnosed with advanced-stage ovarian carcinoma (FIGO stages III-IV) were evaluated for caveolin-1 expression using immunohistochemistry. Patients were divided into long-term survivors and short-term survivors based on disease outcome. Twenty nonneoplastic fallopian tubes and ovaries were additionally studied. RESULTS: The mean follow-up period was 70 months. The mean values for disease-free survival and overall survival were 109 and 125 months for long-term survivors, compared to 3 and 21 months for short-term survivors, respectively. Caveolin-1 expression was localized to the cell membrane in 24/76 (32%) specimens and was detected in the cytoplasm in 52/76 (68%) cases. Both patterns were more often detected in metastases, when compared with primary tumors. In addition, membrane immunoreactivity was more often seen in tumor of short-term survivors. These differences did not reach statistical significance (P > 0.05). Combined membrane and cytoplasmic immunoreactivity was seen in 17/20 (85%) nonneoplastic lesions. Despite its role in tyrosine-kinase-mediated signal transduction in vitro studies, caveolin-1 expression in carcinomas showed no association with the protein expression of c-erbB-2 and epidermal growth factor receptor, evaluated in a previous study of this patient cohort. CONCLUSIONS: This study provides the first in vivo evidence of caveolin-1 membrane expression in human malignancies. Caveolin-1 is often expressed in advanced-stage ovarian carcinoma, but does not appear to be a powerful predictor of disease outcome in these tumors. The reduced expression level in carcinomas compared to nonneoplastic epithelium may point to a role for caveolin-1 as a tumor suppressor gene. Copyright 2001 Academic Press.
OBJECTIVE: The aim of this study was to analyze the correlation among the expression of caveolin-1, the protein constituent of caveolae, and disease outcome in advanced-stage ovarian carcinomas. METHODS: Sections from 76 primary ovarian carcinomas and metastatic lesions from 45 patients diagnosed with advanced-stage ovarian carcinoma (FIGO stages III-IV) were evaluated for caveolin-1 expression using immunohistochemistry. Patients were divided into long-term survivors and short-term survivors based on disease outcome. Twenty nonneoplastic fallopian tubes and ovaries were additionally studied. RESULTS: The mean follow-up period was 70 months. The mean values for disease-free survival and overall survival were 109 and 125 months for long-term survivors, compared to 3 and 21 months for short-term survivors, respectively. Caveolin-1 expression was localized to the cell membrane in 24/76 (32%) specimens and was detected in the cytoplasm in 52/76 (68%) cases. Both patterns were more often detected in metastases, when compared with primary tumors. In addition, membrane immunoreactivity was more often seen in tumor of short-term survivors. These differences did not reach statistical significance (P > 0.05). Combined membrane and cytoplasmic immunoreactivity was seen in 17/20 (85%) nonneoplastic lesions. Despite its role in tyrosine-kinase-mediated signal transduction in vitro studies, caveolin-1 expression in carcinomas showed no association with the protein expression of c-erbB-2 and epidermal growth factor receptor, evaluated in a previous study of this patient cohort. CONCLUSIONS: This study provides the first in vivo evidence of caveolin-1 membrane expression in humanmalignancies. Caveolin-1 is often expressed in advanced-stage ovarian carcinoma, but does not appear to be a powerful predictor of disease outcome in these tumors. The reduced expression level in carcinomas compared to nonneoplastic epithelium may point to a role for caveolin-1 as a tumor suppressor gene. Copyright 2001 Academic Press.
Authors: Russell J Schilder; William E Brady; Heather A Lankes; James V Fiorica; Mark S Shahin; Xun C Zhou; Robert S Mannel; Harsh B Pathak; Wei Hu; R Katherine Alpaugh; Anil K Sood; Andrew K Godwin Journal: Gynecol Oncol Date: 2012-06-16 Impact factor: 5.482
Authors: Márk Juhász; Jie Chen; Zsolt Tulassay; Peter Malfertheiner; Matthias P A Ebert Journal: J Cancer Res Clin Oncol Date: 2003-07-25 Impact factor: 4.553
Authors: T Qayyum; G Fyffe; M Duncan; P A McArdle; M Hilmy; C Orange; G Halbert; M Seywright; P G Horgan; M A Underwood; J Edwards Journal: Br J Cancer Date: 2012-02-21 Impact factor: 7.640
Authors: Y Ito; H Yoshida; K Nakano; K Kobayashi; T Yokozawa; K Hirai; F Matsuzuka; N Matsuura; K Kakudo; K Kuma; A Miyauchi Journal: Br J Cancer Date: 2002-03-18 Impact factor: 7.640
Authors: Lynda M McEvoy; Sharon A O'Toole; Cathy D Spillane; Cara M Martin; Michael F Gallagher; Britta Stordal; Gordon Blackshields; Orla Sheils; John J O'Leary Journal: BMC Cancer Date: 2015-07-25 Impact factor: 4.430